Ethosuximide

Ethosuximide is a medicine used to treat a specific type of seizure called absence seizures. These seizures cause a brief loss of awareness, like staring blankly. Ethosuximide helps stop these seizures from happening.

Brand names:Emeside, Zarontin
Medication

What people taking Ethosuximide report

Every report comes from a Lived member, sent anonymously.

Have you tried Ethosuximide for Absence Epilepsy?

NameHow it went

About Ethosuximide

What It's For

Ethosuximide, sold under the brand name Zarontin and as a generic, is a prescription antiseizure medicine used to control absence seizures, sometimes still called petit mal seizures. An absence seizure is a sudden, brief lapse of awareness, often lasting only seconds, in which a person stops what they are doing, stares and does not respond. These seizures usually begin in childhood or adolescence and can happen many times a day, which is why they are sometimes mistaken for daydreaming or inattention at school. For children and teenagers whose only seizures are absence seizures, ethosuximide is often the first medicine tried. In a large trial of children with newly diagnosed childhood absence epilepsy, it controlled seizures about as well as valproic acid (Depakote is one valproate brand) and better than lamotrigine, with fewer effects on attention than valproic acid. Its role is narrow, though: it probably does not prevent tonic-clonic seizures (the convulsive type once called grand mal), so people who have both kinds usually need a different or additional medicine.

How It Works

Absence seizures are thought to start in a loop of signals between the thalamus, a relay center deep in the brain, and the outer layer of the brain. Tiny gates in nerve cells called T-type calcium channels help drive the rhythmic firing in this loop. When the rhythm locks in, it produces a characteristic pattern on an EEG (a recording of the brain's electrical activity) of about three spike-and-wave bursts per second, and the person briefly loses awareness. Ethosuximide blocks T-type calcium channels, which dampens that rhythm and suppresses the spike-and-wave activity. Because this mechanism is specific to the circuit behind absence seizures, the medicine has little effect on other seizure types.

Dosage & Administration

Ethosuximide is taken by mouth as a 250 mg capsule or as a liquid containing 250 mg in each 5 mL, which is often easier for young children. It is taken once a day or split into more than one daily dose, at about the same times each day. The prescriber starts with a low dose and raises it in small steps, typically every four to seven days, until seizures are controlled with side effects that are manageable. Children's doses are usually based on weight. Do not stop ethosuximide suddenly. Abrupt stopping can bring on absence status, a prolonged state of repeated or continuous absence seizures, so any reduction is done gradually with the prescriber. If a dose is missed, take it when remembered unless the next dose is nearly due, and do not double up.

Side Effects

Stomach upset is the most common problem: loss of appetite, nausea, vomiting, cramps, stomach pain, diarrhea and sometimes weight loss. Drowsiness, headache, dizziness, hiccups, tiredness and unsteadiness also occur. Some children become irritable or hyperactive, have trouble concentrating or sleeping, or have night terrors. These effects are often worst when starting or after a dose increase, and are worth raising with the prescriber if they persist. Rare but serious reactions need prompt attention. Ethosuximide can occasionally lower blood cell counts, including the white cells that fight infection and the platelets that help blood clot, so periodic blood tests are done; call the prescriber promptly about a sore throat, fever or other signs of infection. Contact the prescriber immediately about any new rash, because it can be the first sign of a serious skin reaction such as Stevens-Johnson syndrome, which usually appears within the first month. Fever with swollen glands or facial swelling, even without a rash, can signal a multi-organ allergic reaction and needs same-day medical evaluation. Joint or muscle pain or swelling should also be reported promptly; rarely, ethosuximide causes a drug-induced form of lupus, an immune condition that inflames joints and other tissues.

Interactions & Warnings

Ethosuximide should not be taken by anyone who has had an allergic reaction to it or to related succinimide medicines such as methsuximide (Celontin). It is used with extra caution, and periodic urine and liver tests, in people with liver or kidney disease. It can interact with other seizure medicines. It may raise blood levels of phenytoin (Dilantin), and valproic acid can push ethosuximide levels either up or down, so blood levels may be checked when these are combined or changed. Tell the prescriber and pharmacist about all other medicines and supplements. Ethosuximide can cause drowsiness, so driving or similar tasks should wait until its effects are known. Like all antiseizure medicines, ethosuximide carries an FDA warning about a small increase in suicidal thoughts or behavior. Families and caregivers should watch for new or worsening depression, unusual changes in mood or behavior, or talk of self-harm, and report them to the prescriber right away. Ethosuximide crosses the placenta and passes into breast milk, and birth defects have been reported with antiseizure medicines, including this one. Uncontrolled seizures also carry risks, so anyone who is pregnant, planning pregnancy or breastfeeding should make a plan with the prescriber rather than stopping the medicine on their own.

What to Expect

Because the dose is raised step by step, it can take several weeks to reach the dose that controls seizures. Progress is judged by fewer staring spells reported by family and teachers, and sometimes by a repeat EEG, during which breathing quickly for a few minutes can trigger an absence seizure if they are still occurring. A blood level of the medicine may be measured to guide dosing; levels between about 40 and 100 micrograms per milliliter are the usual target range, though dose decisions also depend on how well seizures are controlled. Not everyone responds. In the major childhood trial, roughly half of children starting ethosuximide were still doing well on it after four months; others switched because seizures continued or side effects were not tolerated. Valproic acid and lamotrigine are the main alternatives. Ongoing care includes periodic blood counts and, as advised, urine and liver tests. Many children outgrow childhood absence epilepsy, so after a period without seizures the care team may discuss slowly tapering the medicine, but new tonic-clonic seizures at any point call for a review of treatment.

Questions to Ask Your Doctor

  1. 1.Are absence seizures my only seizure type, and is ethosuximide the best first choice compared with valproic acid or lamotrigine?
  2. 2.How will we know whether the dose is working, and will we use EEGs or blood levels to check?
  3. 3.Which side effects should I report right away, and how often will blood tests be needed?
  4. 4.How long might treatment last, and when could we consider tapering off?
  5. 5.If pregnancy is possible now or in the future, how should we plan treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.